Shopping Cart
Remove All
Your shopping cart is currently empty
Vulinacimab (HLX-06), an anti-VEGFR-2 monoclonal antibody (mAb), plays a pivotal role in cancer research due to VEGFR-2's significant involvement in angiogenesis, as well as the proliferation, survival, migration, and differentiation of endothelial cells, processes critical for tumor growth where VEGFR-2 is overexpressed [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Backorder | Backorder |
| Description | Vulinacimab (HLX-06), an anti-VEGFR-2 monoclonal antibody (mAb), plays a pivotal role in cancer research due to VEGFR-2's significant involvement in angiogenesis, as well as the proliferation, survival, migration, and differentiation of endothelial cells, processes critical for tumor growth where VEGFR-2 is overexpressed [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2250342-36-8 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.